# Ataibeckley's BPL-003 Shows Rapid, Durable Antidepressant Response In Treatment-Resistant Depression Patients On Ssris Phase 2A Data Published In CNS Drugs

- URL: https://theranews.net/blog/2026-04-09-ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response-in-treatment-re-ed4722/
- Published: 2026-04-09
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: menafn
- Original report: https://menafn.com/1110956527/Ataibeckleys-BPL-003-Shows-Rapid-Durable-Antidepressant-Response-In-Treatment-Resistant-Depression-Patients-On-Ssris-Phase-2A-Data-Published-In-CNS-Drugs
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> 66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts ...

---
AtaiBeckley's investigational drug BPL-003 has demonstrated promising results in treating depression that persists despite SSRI therapy. A Phase 2a trial published in CNS Drugs showed a 66.7% response rate by Day 2 with a single intranasal dose of BPL-003, maintained through Week 12 in the 10 mg cohort. The study provides the first Phase 2a evidence that BPL-003 can be administered alongside SSRIs without compromising efficacy or safety—a meaningful advance for the estimated 30% of depression patients globally with treatment-resistant depression.

## Study Design and Results

The 12-week open-label trial enrolled 12 adults aged 18 to 75 years with moderate-to-severe major depressive disorder (baseline MADRS score of 24 or higher) and treatment-resistant depression. All participants had failed at least two prior antidepressants and remained on a stable dose of one of four SSRIs—citalopram, escitalopram, sertraline, or fluoxetine. Six participants received a single intranasal 10 mg dose of BPL-003 and six received a single intranasal 12 mg dose, with psychological support before, during, and after dosing. Part 1 of the four-part Phase 2a study, published in the Journal of Psychopharmacology in March 2026, reported a mean 12.6-point MADRS reduction by Day 2, sustained through 12 weeks. Part 3 topline data, announced in September 2025, showed that a second dose at Week 2 has the potential to induce additional MADRS reductions without impact on safety and tolerability.

## Clinical Implications

According to Dr. Kevin Craig, Chief Medical Officer at AtaiBeckley, rapid resolution of acute effects and approximately 100-minute discharge readiness "further support the feasibility of integrating BPL-003 into existing interventional psychiatry settings." BPL-003 has been granted Breakthrough Therapy designation by the FDA and is covered by granted U.S., U.K., and European composition-of-matter patents. The company plans to initiate Phase 3 trials in Q2 2026, with Part 4 data on a two-dose induction regimen expected in Q4 2026.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://menafn.com/1110956527/Ataibeckleys-BPL-003-Shows-Rapid-Durable-Antidepressant-Response-In-Treatment-Resistant-Depression-Patients-On-Ssris-Phase-2A-Data-Published-In-CNS-Drugs](https://menafn.com/1110956527/Ataibeckleys-BPL-003-Shows-Rapid-Durable-Antidepressant-Response-In-Treatment-Resistant-Depression-Patients-On-Ssris-Phase-2A-Data-Published-In-CNS-Drugs)*